The role of anti–factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis
Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 3 (4) · 100206
DOI: 10.1016/j.bvth.2026.100206 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Jeffrey Jang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA.
- Division of Hematology and Medical Oncology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA.
Zitieren
APA
Jang, J., Zheng, D., Nold, T., Deng, F., Park, D., Chao, E., Hwang, A., & Huang, C. (2026). The role of anti–factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis. Blood Vessels, Thrombosis & Hemostasis, 3(4), 100206. https://doi.org/10.1016/j.bvth.2026.100206
Vancouver
Jang J, Zheng D, Nold T, Deng F, Park D, Chao E, et al. The role of anti–factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis. Blood Vessels, Thrombosis & Hemostasis. 2026;3(4):100206. doi:10.1016/j.bvth.2026.100206
BibTeX
@article{Jang2026,
author = {Jang, Jeffrey and Zheng, Dominick and Nold, Timothy and Deng, Frank and Park, Daniel and Chao, Eugene and Hwang, Andrew and Huang, Charity},
title = {The role of anti–factor Xa in patients with cancer receiving prophylactic low-molecular-weight heparin: a meta-analysis},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
volume = {3},
number = {4},
pages = {100206},
doi = {10.1016/j.bvth.2026.100206}
}
EUVIMED